Hippo Eyes Earnings With Bulls in Charge and a Lennar Exit to Explain

HIPO heads into its October 29 earnings release with the stock up 23% over the past month, options positioning tilted bullish, and a notable change in the activist register that has yet to fully play out in the narrative.

The clearest market signal is in options. Call positioning dominates the options book, with the put/call ratio at 0.33, well below its 20-day average of 0.35 and near the low end of its 52-week range of 0.02 to 0.93. That is not a defensive setup heading into a print. It reflects genuine bullish lean, not a hedge book. The stock itself has pulled back roughly 2% over the past week to $37.71, a mild fade after a sharp run, but the one-month performance of 23% frames the print as a test of whether that rally has fundamental support.

Short interest is not the story here. At 3.9% of the free float, with borrowing costs falling sharply (down 36% on the week to just 0.33%) and availability running at an extraordinarily loose 3,611%, there is no meaningful short-side pressure heading into the event. Short interest has crept up about 7% over the week, but from a low base, and the borrow market signals no squeeze dynamics whatsoever.

The more newsworthy angle is on the register. LEN FW Investor, an activist filer with a Schedule 13D, has reduced its stake dramatically, from 8.6% to just 0.1%, as last disclosed in February. That is a near-complete exit. The Lennar Foundation still holds 8% (as last disclosed in March), but the activist position, once the single most prominent on the register, has effectively gone. ORTEX's register shows the filing is an amendment, not a new position; stakes are as last disclosed around the 5% threshold, and a holder falling below it may not file again. Separately, the CEO Richard McCathron has been selling steadily under a 10b5-1 plan, shedding 10,000 shares across two transactions in September and October for around $332,000 combined. These are pre-arranged sales, not discretionary decisions, but the pattern is worth noting ahead of the print.

Analysts are split in a familiar way for an InsurTech in recovery mode. Keefe, Bruyette & Woods sits at Market Perform with a $35 target (raised after the August print), while B. Riley and JMP Securities both carry Buy-equivalent ratings with targets in the $41 to $45 range. The consensus mean target of $40.88 sits modestly above the current price, but the spread between the cautious and the optimistic is wide. The company's EPS surprise factor ranks in the 94th percentile, making a beat the base expectation rather than a stretch. The PE multiple has contracted to 11.2 times over the past 30 days even as the stock rallied, meaning earnings have grown faster than the price, a configuration that gives bulls their clearest argument. The last two quarterly prints saw the stock gain roughly 1% and 5% on the day respectively, with the five-day follow-through reaching 12% after the July result.

The print will test whether the underwriting margin recovery that drove the past month's rally is durable enough to justify the recent rerate, and what, if anything, management says about the strategic implications of Lennar's near-total exit from the activist register.